NCT06061809Phase 2Active not recruiting

N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma

Study sponsor: ImmunityBio, Inc. · IBRX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2029-12-31Estimated
Enrollment · participants34Estimated
Source updated2026-07-01Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview